Moleculin Biotech Inc (MBRX) Actualités

Form 8-K - Current report

Form 8-K - Current report

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026

Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML...

Form 8-K - Current report

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model

Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in...

Form EFFECT - Notice of Effectiveness

Form POS AM - Post-Effective amendments for registration statement

Form 8-K - Current report

Form 8-K - Current report

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML

New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML PR Newswire HOUSTON, Nov...

Form 8-K - Current report

Form 8-K - Current report

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025

Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML...